HUMA$0.4263+7.08%
Humacyte, Inc.
Sector: Biological Products, (No Diagnostic Substances)Industry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$118.43M
Float & O/S:
Inst Own:
DilutionScan read 48 of Humacyte, Inc.'s SEC filings and found 9 warrant series, 1 convertible, 2 ATM programs, 1 equity line, 1 shelf registration and 4 completed offerings on file for HUMA. The latest dilution event on file is ATM sales on Jun 30, 2026. Analysis updated Oct 31, 2026.
Signal8 Summary
HUMA
Going-concern warning from auditors
Snapshot
Humacyte is a small-cap biotechnology company developing bioengineered blood vessels. While the company recently generated its first meaningful revenue ($2.0M in FY 2025) and reported positive Phase 3 trial data, the financial picture is critical.
What's Happening Right Now
- : Humacyte priced a public offering of 47.6 million shares at $1.05 per share to raise roughly $50 million in gross proceeds to extend its cash runway.
- : Humacyte reported positive interim results from a Phase 3 trial, with the ATEV meeting its primary endpoint for female dialysis patients and showing significantly lower infection rates.
- : Symvess is now under contract with the U.S. Department of Veterans Affairs Strategic Acquisition Center, making the product available to 170 VA hospitals.
- : The company filed a 10-Q stating it does not have sufficient liquidity to fund operations beyond one year, raising substantial doubt about its ability to continue as a going concern.
